These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37318757)

  • 1. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
    Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
    Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States.
    Zou D; Ye W; Hess LM; Bhandari NR; Ale-Ali A; Foster J; Quon P; Harris M
    J Mol Diagn; 2022 Aug; 24(8):901-914. PubMed ID: 35688357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
    Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
    JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
    Paz-Ares L; Gondos A; Saldana D; Thomas M; Mascaux C; Bubendorf L; Barlesi F
    Lung Cancer; 2022 May; 167():41-48. PubMed ID: 35397297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States.
    Bruno DS; Hess LM; Li X; Su EW; Patel M
    JCO Precis Oncol; 2022 Jun; 6():e2100427. PubMed ID: 35737912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
    Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
    Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
    Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
    Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing Genomic Testing for Lung Cancer Into Routine Clinical Practice - The Welsh Experience.
    Cox S; Powell C; Morgan S
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):716-723. PubMed ID: 36088167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
    Stricker T; Jain N; Ma E; Yu E; Wang R; Schuldt R; Price R; Szado T; Sussell J; Ogale S; Lin V; Arrowsmith E; Slater D; Vaena D; Staszewski H; Fang B; Seneviratne L; Daniel D
    Oncologist; 2024 Jun; 29(6):534-542. PubMed ID: 38417095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer.
    Matsuda H; Ogawa T; Sadatsuki Y; Tsujino T; Wada S; Kim SW; Hatanaka Y
    Respir Investig; 2023 Jan; 61(1):61-73. PubMed ID: 36460584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
    Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
    Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
    Sireci AN; Krein PM; Hess LM; Khan T; Willey J; Ayars M; Deyoung K; Bhaskar S; Mumuney G; Coutinho A
    Clin Lung Cancer; 2023 Jul; 24(5):429-436. PubMed ID: 37080814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Raez LE; Brice K; Dumais K; Lopez-Cohen A; Wietecha D; Izquierdo PA; Santos ES; Powery HW
    Clin Lung Cancer; 2023 Mar; 24(2):120-129. PubMed ID: 36585341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
    Bonanno L; Pavan A; Ferro A; Calvetti L; Frega S; Pasello G; Aprile G; Guarneri V; Conte P;
    Oncologist; 2020 Dec; 25(12):e1996-e2005. PubMed ID: 32557976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices.
    Wong W; Wu N; Gupta R; Mansfield AS
    Clin Lung Cancer; 2021 May; 22(3):e470-e480. PubMed ID: 32763067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.
    Mileham KF; Schenkel C; Bruinooge SS; Freeman-Daily J; Basu Roy U; Moore A; Smith RA; Garrett-Mayer E; Rosenthal L; Garon EB; Johnson BE; Osarogiagbon RU; Jalal S; Virani S; Weber Redman M; Silvestri GA
    Cancer Med; 2022 Jan; 11(2):530-538. PubMed ID: 34921524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
    Bestvina CM; Waters D; Morrison L; Emond B; Lafeuille MH; Hilts A; Lefebvre P; He A; Vanderpoel J
    J Med Econ; 2024; 27(1):292-303. PubMed ID: 38391239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing.
    Sheinson DM; Wong WB; Flores C; Ogale S; Gross CP
    JCO Oncol Pract; 2021 Nov; 17(11):e1774-e1784. PubMed ID: 34043456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.